Dexamethasone  ||| S:0 E:14 ||| NNP
reduces  ||| S:14 E:22 ||| VBZ
nausea  ||| S:22 E:29 ||| VBN
and  ||| S:29 E:33 ||| CC
vomiting  ||| S:33 E:42 ||| NN
but  ||| S:42 E:46 ||| CC
not  ||| S:46 E:50 ||| RB
pain  ||| S:50 E:55 ||| VBN
after  ||| S:55 E:61 ||| IN
thyroid  ||| S:61 E:69 ||| JJ
surgery ||| S:69 E:76 ||| NN
:  ||| S:76 E:78 ||| :
a  ||| S:78 E:80 ||| DT
meta-analysis  ||| S:80 E:94 ||| JJ
of  ||| S:94 E:97 ||| IN
randomized  ||| S:97 E:108 ||| FW
controlled  ||| S:108 E:119 ||| FW
trials  ||| S:119 E:126 ||| FW
Postoperative  ||| S:126 E:140 ||| FW
nausea  ||| S:140 E:147 ||| FW
and  ||| S:147 E:151 ||| CC
vomiting  ||| S:151 E:160 ||| NNS
( ||| S:160 E:161 ||| -LRB-
PONV ||| S:161 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
is  ||| S:167 E:170 ||| VBZ
a  ||| S:170 E:172 ||| DT
common  ||| S:172 E:179 ||| JJ
complication  ||| S:179 E:192 ||| NN
after  ||| S:192 E:198 ||| IN
thyroidectomy ||| S:198 E:211 ||| NN
.  ||| S:211 E:213 ||| .
The  ||| S:213 E:217 ||| DT
aim  ||| S:217 E:221 ||| NN
of  ||| S:221 E:224 ||| IN
this  ||| S:224 E:229 ||| DT
article  ||| S:229 E:237 ||| NN
was  ||| S:237 E:241 ||| VBD
to  ||| S:241 E:244 ||| TO
evaluate  ||| S:244 E:253 ||| VB
the  ||| S:253 E:257 ||| DT
efficacy  ||| S:257 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
dexamethasone  ||| S:269 E:283 ||| NN
for  ||| S:283 E:287 ||| IN
prevention  ||| S:287 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
PONV  ||| S:301 E:306 ||| NNP
and  ||| S:306 E:310 ||| CC
pain  ||| S:310 E:315 ||| NN
in  ||| S:315 E:318 ||| IN
patients  ||| S:318 E:327 ||| NNS
undergoing  ||| S:327 E:338 ||| VBG
thyroidectomy ||| S:338 E:351 ||| NNS
.  ||| S:351 E:353 ||| .
We  ||| S:353 E:356 ||| PRP
performed  ||| S:356 E:366 ||| VBD
this  ||| S:366 E:371 ||| DT
meta-analysis  ||| S:371 E:385 ||| JJ
based  ||| S:385 E:391 ||| VBN
on  ||| S:391 E:394 ||| IN
the  ||| S:394 E:398 ||| DT
QUORUM  ||| S:398 E:405 ||| NNP
( ||| S:405 E:406 ||| -LRB-
Quality  ||| S:406 E:414 ||| NNP
of  ||| S:414 E:417 ||| IN
Reporting  ||| S:417 E:427 ||| NNP
of  ||| S:427 E:430 ||| IN
Meta-analyses ||| S:430 E:443 ||| NNP
)  ||| S:443 E:445 ||| -RRB-
guidelines ||| S:445 E:455 ||| NNS
.  ||| S:455 E:457 ||| .
Our  ||| S:457 E:461 ||| PRP$
study  ||| S:461 E:467 ||| NN
included  ||| S:467 E:476 ||| VBD
randomized  ||| S:476 E:487 ||| VBN
controlled  ||| S:487 E:498 ||| VBN
trials  ||| S:498 E:505 ||| NNS
( ||| S:505 E:506 ||| -LRB-
RCTs ||| S:506 E:510 ||| NNP
)  ||| S:510 E:512 ||| -RRB-
that  ||| S:512 E:517 ||| IN
compared  ||| S:517 E:526 ||| VBN
preoperative  ||| S:526 E:539 ||| JJ
single-dose  ||| S:539 E:551 ||| JJ
administration  ||| S:551 E:566 ||| NN
of  ||| S:566 E:569 ||| IN
dexamethasone  ||| S:569 E:583 ||| NN
with  ||| S:583 E:588 ||| IN
no  ||| S:588 E:591 ||| DT
dexamethasone  ||| S:591 E:605 ||| NN
in  ||| S:605 E:608 ||| IN
patients  ||| S:608 E:617 ||| NNS
undergoing  ||| S:617 E:628 ||| VBG
thyroidectomy ||| S:628 E:641 ||| NNS
.  ||| S:641 E:643 ||| .
The  ||| S:643 E:647 ||| DT
primary  ||| S:647 E:655 ||| JJ
outcome  ||| S:655 E:663 ||| NN
was  ||| S:663 E:667 ||| VBD
occurrence  ||| S:667 E:678 ||| JJ
and  ||| S:678 E:682 ||| CC
severity  ||| S:682 E:691 ||| NN
of  ||| S:691 E:694 ||| IN
PONV ||| S:694 E:698 ||| NNP
,  ||| S:698 E:700 ||| ,
and  ||| S:700 E:704 ||| CC
the  ||| S:704 E:708 ||| DT
secondary  ||| S:708 E:718 ||| JJ
outcomes  ||| S:718 E:727 ||| NNS
included  ||| S:727 E:736 ||| VBD
pain ||| S:736 E:740 ||| NN
,  ||| S:740 E:742 ||| ,
use  ||| S:742 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
analgesics ||| S:749 E:759 ||| NN
,  ||| S:759 E:761 ||| ,
and  ||| S:761 E:765 ||| CC
steroid-related  ||| S:765 E:781 ||| JJ
complications ||| S:781 E:794 ||| NNS
.  ||| S:794 E:796 ||| .
Seven  ||| S:796 E:802 ||| CD
RCTs  ||| S:802 E:807 ||| NN
were  ||| S:807 E:812 ||| VBD
included ||| S:812 E:820 ||| VBN
,  ||| S:820 E:822 ||| ,
with  ||| S:822 E:827 ||| IN
a  ||| S:827 E:829 ||| DT
total  ||| S:829 E:835 ||| NN
of  ||| S:835 E:838 ||| IN
611  ||| S:838 E:842 ||| CD
patients ||| S:842 E:850 ||| NNS
.  ||| S:850 E:852 ||| .
A  ||| S:852 E:854 ||| DT
statistically  ||| S:854 E:868 ||| NN
and  ||| S:868 E:872 ||| CC
clinically  ||| S:872 E:883 ||| RB
significant  ||| S:883 E:895 ||| JJ
difference  ||| S:895 E:906 ||| NN
in  ||| S:906 E:909 ||| IN
the  ||| S:909 E:913 ||| DT
incidence  ||| S:913 E:923 ||| NN
and  ||| S:923 E:927 ||| CC
severity  ||| S:927 E:936 ||| NN
of  ||| S:936 E:939 ||| IN
PONV  ||| S:939 E:944 ||| NNP
was  ||| S:944 E:948 ||| VBD
found  ||| S:948 E:954 ||| VBN
in  ||| S:954 E:957 ||| IN
favor  ||| S:957 E:963 ||| NN
of  ||| S:963 E:966 ||| IN
dexamethasone  ||| S:966 E:980 ||| NNS
( ||| S:980 E:981 ||| -LRB-
SMD ||| S:981 E:984 ||| NNP
,  ||| S:984 E:986 ||| ,
0.23 ||| S:986 E:990 ||| CD
;  ||| S:990 E:992 ||| :
95 ||| S:992 E:994 ||| CD
%  ||| S:994 E:996 ||| NN
CI ||| S:996 E:998 ||| NNP
,  ||| S:998 E:1000 ||| ,
0.13-0.41 ||| S:1000 E:1009 ||| NNP
;  ||| S:1009 E:1011 ||| :
P  ||| S:1011 E:1012 ||| NNP
< ||| S:1012 E:1013 ||| SYM
0.00001 ||| S:1013 E:1020 ||| NNP
;  ||| S:1020 E:1022 ||| :
SMD ||| S:1022 E:1025 ||| NNP
,  ||| S:1025 E:1027 ||| ,
0.53 ||| S:1027 E:1031 ||| CD
;  ||| S:1031 E:1033 ||| :
95 ||| S:1033 E:1035 ||| CD
%  ||| S:1035 E:1037 ||| NN
CI ||| S:1037 E:1039 ||| NNP
,  ||| S:1039 E:1041 ||| ,
-1.03  ||| S:1041 E:1047 ||| CD
to  ||| S:1047 E:1050 ||| TO
-0.03 ||| S:1050 E:1055 ||| CD
;  ||| S:1055 E:1057 ||| :
P=0.04 ||| S:1057 E:1063 ||| CD
) ||| S:1063 E:1064 ||| -RRB-
.  ||| S:1064 E:1066 ||| .
However ||| S:1066 E:1073 ||| RB
,  ||| S:1073 E:1075 ||| ,
there  ||| S:1075 E:1081 ||| EX
was  ||| S:1081 E:1085 ||| VBD
no  ||| S:1085 E:1088 ||| DT
significant  ||| S:1088 E:1100 ||| JJ
difference  ||| S:1100 E:1111 ||| NN
in  ||| S:1111 E:1114 ||| IN
reduction  ||| S:1114 E:1124 ||| NN
of  ||| S:1124 E:1127 ||| IN
pain  ||| S:1127 E:1132 ||| NN
severity  ||| S:1132 E:1141 ||| NN
and  ||| S:1141 E:1145 ||| CC
analgesic  ||| S:1145 E:1155 ||| JJ
consumption  ||| S:1155 E:1167 ||| NN
in  ||| S:1167 E:1170 ||| IN
using  ||| S:1170 E:1176 ||| VBG
dexamethasone  ||| S:1176 E:1190 ||| NNS
( ||| S:1190 E:1191 ||| -LRB-
SMD ||| S:1191 E:1194 ||| NNP
,  ||| S:1194 E:1196 ||| ,
-0.83 ||| S:1196 E:1201 ||| NNP
;  ||| S:1201 E:1203 ||| :
95 ||| S:1203 E:1205 ||| CD
%  ||| S:1205 E:1207 ||| NN
CI ||| S:1207 E:1209 ||| NNP
,  ||| S:1209 E:1211 ||| ,
-1.85  ||| S:1211 E:1217 ||| CD
to  ||| S:1217 E:1220 ||| TO
0.18 ||| S:1220 E:1224 ||| CD
;  ||| S:1224 E:1226 ||| :
P=0.14 ||| S:1226 E:1232 ||| CD
;  ||| S:1232 E:1234 ||| :
SMD ||| S:1234 E:1237 ||| NNP
,  ||| S:1237 E:1239 ||| ,
-0.19 ||| S:1239 E:1244 ||| NNP
;  ||| S:1244 E:1246 ||| :
95 ||| S:1246 E:1248 ||| CD
%  ||| S:1248 E:1250 ||| NN
CI ||| S:1250 E:1252 ||| NNP
,  ||| S:1252 E:1254 ||| ,
-0.43  ||| S:1254 E:1260 ||| CD
to  ||| S:1260 E:1263 ||| TO
0.04 ||| S:1263 E:1267 ||| CD
;  ||| S:1267 E:1269 ||| :
P=0.10 ||| S:1269 E:1275 ||| CD
) ||| S:1275 E:1276 ||| -RRB-
.  ||| S:1276 E:1278 ||| .
No  ||| S:1278 E:1281 ||| DT
steroid-related  ||| S:1281 E:1297 ||| JJ
complications  ||| S:1297 E:1311 ||| NNS
were  ||| S:1311 E:1316 ||| VBD
noted ||| S:1316 E:1321 ||| VBN
.  ||| S:1321 E:1323 ||| .
A  ||| S:1323 E:1325 ||| DT
single  ||| S:1325 E:1332 ||| JJ
preoperative  ||| S:1332 E:1345 ||| JJ
administration  ||| S:1345 E:1360 ||| NN
of  ||| S:1360 E:1363 ||| IN
dexamethasone  ||| S:1363 E:1377 ||| NN
reduced  ||| S:1377 E:1385 ||| VBD
the  ||| S:1385 E:1389 ||| DT
incidence  ||| S:1389 E:1399 ||| NN
and  ||| S:1399 E:1403 ||| CC
severity  ||| S:1403 E:1412 ||| NN
of  ||| S:1412 E:1415 ||| IN
PONV  ||| S:1415 E:1420 ||| NNP
but  ||| S:1420 E:1424 ||| CC
not  ||| S:1424 E:1428 ||| RB
pain  ||| S:1428 E:1433 ||| JJ
severity  ||| S:1433 E:1442 ||| NN
and  ||| S:1442 E:1446 ||| CC
analgesic  ||| S:1446 E:1456 ||| JJ
consumption  ||| S:1456 E:1468 ||| NN
in  ||| S:1468 E:1471 ||| IN
patients  ||| S:1471 E:1480 ||| NNS
undergoing  ||| S:1480 E:1491 ||| VBG
thyroidectomy ||| S:1491 E:1504 ||| NNS
.  ||| S:1504 E:1506 ||| .
Further  ||| S:1506 E:1514 ||| JJ
studies  ||| S:1514 E:1522 ||| NNS
with  ||| S:1522 E:1527 ||| IN
a  ||| S:1527 E:1529 ||| DT
larger  ||| S:1529 E:1536 ||| JJR
sample  ||| S:1536 E:1543 ||| NN
size  ||| S:1543 E:1548 ||| NN
are  ||| S:1548 E:1552 ||| VBP
needed  ||| S:1552 E:1559 ||| VBN
to  ||| S:1559 E:1562 ||| TO
further  ||| S:1562 E:1570 ||| RB
explore  ||| S:1570 E:1578 ||| VB
the  ||| S:1578 E:1582 ||| DT
efficacy  ||| S:1582 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
dexamethasone  ||| S:1594 E:1608 ||| NN
on  ||| S:1608 E:1611 ||| IN
postoperative  ||| S:1611 E:1625 ||| JJ
pain  ||| S:1625 E:1630 ||| NN
severity  ||| S:1630 E:1639 ||| NN
and  ||| S:1639 E:1643 ||| CC
analgesic  ||| S:1643 E:1653 ||| JJ
consumption ||| S:1653 E:1664 ||| NN
.  ||| S:1664 E:1666 ||| .
